Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imatinib in Acute Ischaemic Stroke: A Phase 3, Randomized, Double-blind, Placebo Controlled, Parallel-arm Efficacy Trial of Imatinib in Acute Ischaemic Stroke

NCT03639922 is registered in ClinicalTrials.gov with Niaz Ahmed as lead sponsor.

NCT NCT03639922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imatinib in Acute Ischaemic Stroke: A Phase 3, Randomized, Double-blind, Placebo Controlled, Parallel-arm Efficacy Trial of Imatinib in Acute Ischaemic Stroke
Lead sponsor
Niaz Ahmed
Phase
Phase 3
Overall status
Unknown status
Start date
October 1, 2018
Completion date
June 30, 2023
Enrollment
1,260 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischaemic stroke